Sclerema Neonatorum

Back

Background

The classic description of sclerema neonatorum (SN) is credited to Underwood, who described it in 1784 and appropriately termed it "skinbound disease." In 1817, Alibert introduced the term sclerema, derived from the Greek word skleros, meaning hard. Sclerema neonatorum is a disorder of the subcutaneous fat in debilitated neonates and is considered best as a sign of a potentially fatal underlying disease process and not a specific disease entity.[1] A thorough review of the nomenclature, clinical findings, histological features, differential diagnosis, and management of sclerema neonatorum was published in 2008.[2]

The Medscape Pediatric Dermatology Resource Center may be of interest.

Pathophysiology

In an infant, fat has a higher saturated-to-unsaturated fatty acid ratio compared to adult fat and thus, a higher melting point. Prematurity, hypothermia, shock, and metabolic abnormalities have been postulated to further increase this ratio, possibly as a result of enzymatic alteration allowing precipitation of fatty acid crystals within the lipocytes. This condition has been suggested to result in the dramatic clinical findings in affected skin. X-ray diffraction techniques have confirmed that infants with sclerema neonatorum have an increase in saturated fats and that the crystals within the fat cells are composed of triglycerides.[3, 4]

Etiology

Associated underlying conditions include pneumonia, septicemia, septic shock, hypothermia, metabolic acidosis, transient hyperammonemia of the newborn, respiratory distress syndrome, congenital heart defects, gastroenteritis, intestinal obstruction, and severe malnutrition.[2, 5, 6, 7] Two case reports have described sclerema neonatorum that developed after therapeutic hypothermia initiated for neonatal asphyxia.[8, 9]

Epidemiology

Frequency

United States

The exact incidence of sclerema neonatorum is unknown. All studies describe sclerema neonatorum as extremely rare. The number of reported cases in recent years has declined, probably as a result of better neonatal care.

International

A 10% incidence of sclerema neonatorum was documented in preterm neonates admitted to a hospital in Bangladesh. Risk factors for developing sclerema neonatorum in these infants included poor feeding, jaundice, and bacteremia.[10]

Race

No racial predilection has been reported.

Sex

Sclerema neonatorum shows a slight male predominance, with an estimated male-to-female ratio of 1.5:1.[11]

Age

Sclerema neonatorum is a disease confined to the newborn period. Sclerema neonatorum can present at birth, but onset within the first week of life is more common. The oldest reported infant presented with Pseudomonas septicemia at age 106 days.

Prognosis

Because sclerema neonatorum invariably is associated with serious underlying disease, the mortality rate is high. In different series, the reported mortality rates range from 67-88%, with death occurring hours to days after onset. If the underlying disease is treated successfully, the skin softens and returns to normal.

One case of an infant with consecutive episodes of sclerema was reported to occur in a severely ill infant, and both episodes resolved after appropriate treatment of underlying illness.[12]

History

Half the infants affected by sclerema neonatorum are premature, and the others are full term but have a serious underlying illness. They are often of low birth weight (Apgar scores

Physical Examination

Physical findings of sclerema neonatorum appear suddenly, first on the thighs and buttocks and then, spreading rapidly, often affecting all parts of the body except the palms, soles, and genitalia. The involved skin is pale, waxy, and firm to palpation. The skin cannot be pitted or pinched up because it is bound to underlying subcutaneous tissue, muscle, and bone. The affected infant often displays flexion contractures at the elbows, knees, and hips; temperature instability; restricted respiration; difficulty in feeding; and decreased spontaneous movement. Newborns may also present with masklike facies or “pseudotrismus,” an inability to completely open the mouth, secondary to the thickening of the skin over the face, arms, and hands.[14]

Complications

Unless the underlying disease is identified and treated, the course of sclerema neonatorum is one of rapid deterioration in the general health of the infant and, ultimately, death.

Laboratory Studies

Laboratory abnormalities associated with sclerema neonatorum correlate with the underlying disease process. Hypoglycemia, metabolic acidosis, respiratory alkalosis, hyperkalemia, hypocalcemia, and elevated blood urea are common, albeit nonspecific, findings. A complete sepsis workup should be initiated in all infants with sclerema neonatorum.

Histologic Findings

Despite the striking clinical presentation, histologic findings of sclerema neonatorum are subtle. The subcutaneous fat may appear normal or may have only sparse inflammation, which, when present, consists of lymphocytes, histiocytes, and multinucleated giant cells. This is thought to reflect the poor immunologic response of the infant.[15] The most consistent findings are edema, a thickening of the subcutaneous fibrous septa, and a radial array of fine, needlelike clefts in the fat cells, representing former sites of fat crystals. The lack of a granulomatous inflammation and the absence of fat necrosis help distinguish sclerema neonatorum from subcutaneous fat necrosis of the newborn (SCFN).[15, 16, 17] Radially arranged needlelike clefts are common to both sclerema neonatorum and SCFN.

See the image below.



View Image

Needle-shaped crystals are arranged radially in adipocytes. Courtesy of DermNet New Zealand (https://www.dermnetnz.org/assets/Uploads/pathology/e/scle....

Medical Care

Recognition and the prompt institution of therapy specific for the underlying disease are mandatory. Careful monitoring, correction of electrolyte abnormalities, respiratory support, correction of hypovolemia, and control of hypothermia are important in sclerema neonatorum patients.

Antibiotics

Some authors advocate the prompt institution of prophylactic broad-spectrum antibiotic therapy for possible associated sepsis.

Systemic steroids

The value of systemic steroids is controversial. No controlled studies have demonstrated improved survival with the use of systemic steroids in sclerema neonatorum, although they are often used and have been observed to limit the extent and development of new lesions.[2, 13, 18]

Exchange transfusions

Several reports document the beneficial effect of exchange transfusions on survival.[1, 3, 4, 19] A randomized controlled trial demonstrated a 50% survival rate in septic neonates with sclerema neonatorum who were treated with exchange transfusion used early in the course of the disease, compared with 5% who were not. Exchange transfusion may enhance humoral and cellular immunity in these immunologically immature neonates, and may improve peripheral and pulmonary circulation, thereby also improving oxygen exchange.[2, 19]

Intravenous immunoglobulin

One case report describes the use of intravenous immunoglobulin in a neonate. There was transient improvement in the skin disease, but thoracic constriction from sclerema neonatorum ultimately led to the child's death.[10]

Consultations

Infants with sclerema neonatorum are best cared for in a neonatal intensive care unit by an intensivist.

Depending on the underlying illness (eg, sepsis), consultation to the appropriate specialists should be made.

Medication Summary

Medical therapy of the skin is not beneficial; successful treatment of the underlying disorder improves the skin.

Author

India Mayo Hill, MD, Resident Physician, Department of Dermatology, University of Alabama at Birmingham School of Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

Craig A Elmets, MD, Professor and Chair, Department of Dermatology, Director, Chemoprevention Program Director, Comprehensive Cancer Center, UAB Skin Diseases Research Center, University of Alabama at Birmingham School of Medicine

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: University of Alabama at Birmingham; University of Alabama Health Services Foundation<br/>Serve(d) as a speaker or a member of a speakers bureau for: Ferndale Laboratories<br/>Received research grant from: NIH, Veterans Administration, California Grape Assn<br/>Received consulting fee from Astellas for review panel membership; Received salary from Massachusetts Medical Society for employment; Received salary from UpToDate for employment. for: Astellas.

Specialty Editors

Richard P Vinson, MD, Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Disclosure: Nothing to disclose.

Van Perry, MD, Assistant Professor, Department of Medicine, Division of Dermatology, University of Texas School of Medicine at San Antonio

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD, Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Disclosure: Nothing to disclose.

Additional Contributors

Daniel Mark Siegel, MD, MS, Clinical Professor of Dermatology, Department of Dermatology, State University of New York Downstate Medical Center

Disclosure: Nothing to disclose.

Acknowledgements

Gloria H Nguyen, MD Cutaneous Oncology Research Fellow, Department of Dermatology, University of Alabama at Birmingham School of Medicine

Gloria H Nguyen, MD is a member of the following medical societies: American College of Physicians

Disclosure: Nothing to disclose.

Amy J Theos, MD Director of Pediatric Dermatology, Associate Professor, Department of Dermatology, University of Alabama at Birmingham

Amy J Theos, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, and Society for Pediatric Dermatology

Disclosure: Nothing to disclose.

References

  1. Warwick WJ, Ruttenberg HD, Quie PG. Sclerema neonatorum--a sign, not a disease. JAMA. 1963 Jun 1. 184:680-3. [View Abstract]
  2. Zeb A, Darmstadt GL. Sclerema neonatorum: a review of nomenclature, clinical presentation, histological features, differential diagnoses and management. J Perinatol. 2008 Jul. 28(7):453-60. [View Abstract]
  3. Kellum RE, Ray TL, Brown GR. Sclerema neonatorum. Report of a case and analysis of subcutaneous and epidermal-dermal lipids by chromatographic methods. Arch Dermatol. 1968 Apr. 97(4):372-80. [View Abstract]
  4. Breukhoven PE, Kerkhof GF, Willemsen RH, Hokken-Koelega AC. Fat mass and lipid profile in young adults born preterm. J Clin Endocrinol Metab. 2012 Apr. 97(4):1294-302. [View Abstract]
  5. Fretzin DF, Arias AM. Sclerema neonatorum and subcutaneous fat necrosis of the newborn. Pediatr Dermatol. 1987 Aug. 4(2):112-22. [View Abstract]
  6. Chisti MJ, Saha S, Roy CN, et al. Predictors of mortality in infants with sclerema presenting to the Centre for Diarrhoeal Disease, Dhaka. Ann Trop Paediatr. 2009 Mar. 29(1):45-50. [View Abstract]
  7. Lindenberg JA, Milstein JM, Cox KL. Sclerema neonatorum: a sign of transient hyperammonemia of the newborn. J Pediatr Gastroenterol Nutr. 1987 May-Jun. 6(3):474-6. [View Abstract]
  8. Battin M, Harding J, Gunn A. Sclerema Neonatorum following hypothermia. J Paediatr Child Health. 2002 Oct. 38(5):533-4. [View Abstract]
  9. Navarini-Meury S, Schneider J, Bührer C. Sclerema neonatorum after therapeutic whole-body hypothermia. Arch Dis Child Fetal Neonatal Ed. 2007 Jul. 92(4):F307. [View Abstract]
  10. Zeb A, Rosenberg RE, Ahmed NU, Saha SK, Chowdhury A, Ahmed S, et al. Risk factors for sclerema neonatorum in preterm neonates in Bangladesh. Pediatr Infect Dis J. 2009 May. 28(5):435-8. [View Abstract]
  11. Bwibo NO, Anderson BT. Sclerema neonatorum (a study of 16 cases in the special care unit, Mulago Hospital, Kampala). East Afr Med J. 1970 Jan. 47(1):50-5. [View Abstract]
  12. Afroze F, Pietroni MA, Chisti MJ. Recurrent sclerema in a young infant presenting with severe sepsis and severe pneumonia: an uncommon but extremely life-threatening condition. J Health Popul Nutr. 2013 Dec. 31:538-42. [View Abstract]
  13. Milunsky A, Levin SE. Sclerema neonatorum: a clinical study of 79 cases. S Afr Med J. 1966 Jul 2. 40(27):638-41. [View Abstract]
  14. Taeusch, HW, Ballard RA, Gleason CA, Avery ME. Avery's Diseases of the Newborn. 8th ed. Philadelphia, PA: Elsevier Saunders; 2005. 1516-8.
  15. Polcari IC, Stein SL. Panniculitis in childhood. Dermatol Ther. 2010 Jul-Aug. 23(4):356-67. [View Abstract]
  16. Lara LG, Villa AV, Rivas MM, Capella MS, Prada F, Enseñat MA. Subcutaneous Fat Necrosis of the Newborn: Report of Five Cases. Pediatr Neonatol. 2017 Feb. 58 (1):85-88. [View Abstract]
  17. Del Pozzo-Magaña BR, Ho N. Subcutaneous Fat Necrosis of the Newborn: A 20-Year Retrospective Study. Pediatr Dermatol. 2016 Nov. 33 (6):e353-e355. [View Abstract]
  18. Shrestha S, Chaudhary N, Koirala S, Gupta R. Sclerema Neonatorum Treated Successfully with Parenteral Steroids: An Experience from a Resource Poor Country. Case Rep Pediatr. 2017. 2017:4836142. [View Abstract]
  19. Sadana S, Mathur NB, Thakur A. Exchange transfusion in septic neonates with sclerema: effect on immunoglobulin and complement levels. Indian Pediatr. 1997 Jan. 34(1):20-5. [View Abstract]

Needle-shaped crystals are arranged radially in adipocytes. Courtesy of DermNet New Zealand (https://www.dermnetnz.org/assets/Uploads/pathology/e/sclerema-neonatorum-fig-2.jpg).

Needle-shaped crystals are arranged radially in adipocytes. Courtesy of DermNet New Zealand (https://www.dermnetnz.org/assets/Uploads/pathology/e/sclerema-neonatorum-fig-2.jpg).